Pyelonephritis impacts on organic anion transporters (OAT) 1 and 3 activity in pregnant women: a quantitative system pharmacology approach

Faculdade de Ciências Farmacêuticas de Ribeirão Preto0 个研究点开始时间: 2021年10月10日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Pregnant women over the age of 18 will be investigated, diagnosed with pyelonephritis and with indication for treatment with antibiotics, seen at HC-FMRPUSP. Additionally, healthy pregnant patients will be recruited at the Women's Health of Ribeirão Preto-Mater (CRSMRP-Mater) and in the following basic units of health and municipal community medical centers Centro Médico Social Comunitário Vila Lobato; CSE Ipiranga / Dr Edgard Aché; UBS Dom Mielle / Prof. Dr. Aymar Baptista Prado; UBS Jardim Presidente Dutra / Dr. Sérgio Botelho da Costa Moares; USD Maria Casagrande Lopes / Ernesto Che Guevara; USF Vila Albertina / Dr. Álvaro Panazzolo; UBS Vila Tibério / Wilma Delphina by O. Garotti; UBS Bonfim Paulista / Mamoro Kobayashi and UBS Santa Cruz / Helio Lourenço de Oliveira and healthy non-pregnant volunteers from the Campus of the University of São Paulo, Campus of Ribeirão Preto. Pregnant patients of both protocols will be included in the study during the second and third quarters of the gestation

•Pregnant women diagnosed with pyelonephritis will be excluded from the study when
•present at least one of the following diseases: chronic renal failure, syndromes
•hypertensive (chronic arterial hypertension and / or pre-eclampsia), chronic fetal distress and systemic lupus erythematosus. Healthy pregnant women and healthy non-pregnant volunteers will be excluded from the protocol when using OAT-inhibiting / inducing drugs, which may interact with furosemide or probenecid: amino salicylic acid, para-aminohipuric acid, citalopram, cholestyramine, escitalopram, diclofenac, digoxin , lithium, linezolid,
•rifampin, rifabutin, rifapentin, sertraline and teriflunomide.

发起方

Faculdade de Ciências Farmacêuticas de Ribeirão Preto